دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
An Integrated Interdisciplinary Sleep Care Model—The Ultimate Dream Team
Sara E. Benjamin, MD1; Elliott N. Exar, MD1; Charlene E. Gamaldo, MD1
doi : 10.1001/jamaneurol.2023.0549
June 2023, Vol 80, No. 6, Pages 540-648
Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain
Ahmed Abdelhak, MD, MRCP1; Jens Kuhle, MD, PhD2,3; Ari J. Green, MD1
Oncogenic Pathways Provide Clue to the Etiology of Human Mesial Temporal Lobe Epilepsy
Alica M. Goldman, MD, PhD, MSc1
Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients
Daniele Altomare, PhD1,2,3; Frederik Barkhof, MD4,5; Camilla Caprioglio, MS1,2; Lyduine E. Collij, PhD4; Philip Scheltens, MD6; Isadora Lopes Alves, PhD4; Femke Bouwman, MD6; Johannes Berkhof, PhD7; Ingrid S. van Maurik, PhD6,7; Valentina Garibotto, MD8,9; Christian Moro, MS1,2; Julien Delrieu, MD10,11; Pierre Payoux, MD12,13; Laure Saint-Aubert, PhD12,13; Anne Hitzel, MD12; José Luis Molinuevo, MD14,15; Oriol Grau-Rivera, MD14,16,17; Juan Domingo Gispert, MD14,16,18; Alexander Drzezga, MD19,20,21; Frank Jessen, MD20,22,23; Philip Zeyen, MD22; Agneta Nordberg, MD24,25; Irina Savitcheva, MD26; Vesna Jelic, MD27; Zuzana Walker, MD28,29; Paul Edison, MD30; Jean-François Demonet, MD31; Rossella Gismondi, MD32; Gill Farrar, PhD33; Andrew W. Stephens, MD32; Giovanni B. Frisoni, MD1,2; for the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Consortium
doi : 10.1001/jamaneurol.2023.0997
Importance Amyloid positron emission tomography (PET) allows the direct assessment of amyloid deposition, one of the main hallmarks of Alzheimer disease. However, this technique is currently not widely reimbursed because of the lack of appropriately designed studies demonstrating its clinical effect.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks
Priya S. Kishnani, MD1; Jordi Diaz-Manera, MD2; Antonio Toscano, MD3; Paula R. Clemens, MD4,5; Shafeeq Ladha, MD6; Kenneth I. Berger, MD7,8; Hani Kushlaf, MD9,10; Volker Straub, MD2; Gerson Carvalho, MD11; Tahseen Mozaffar, MD12; Mark Roberts, MD13; Shahram Attarian, MD14; Yin-Hsiu Chien, MD15; Young-Chul Choi, MD16; John W. Day, MD17,18; Sevim Erdem-Ozdamar, MD19; Sergey Illarioshkin, MD20; Ozlem Goker-Alpan, MD21; Anna Kostera-Pruszczyk, MD22; Ans T. van der Ploeg, MD23; Kristina An Haack, MD24; Olivier Huynh-Ba, MD24; Swathi Tammireddy, MBBS25; Nathan Thibault, PharmD25; Tianyue Zhou, PhD25; Mazen M. Dimachkie, MD26; Benedikt Schoser, MD27; for the COMET Investigator Group
doi : 10.1001/jamaneurol.2023.0552
Importance In the previously reported Comparative Enzyme Replacement Trial With neoGAA Versus rhGAA (COMET) trial, avalglucosidase alfa treatment for 49 weeks showed clinically meaningful improvements in upright forced vital capacity (FVC) percent predicted and 6-minute walk test (6MWT) compared with alglucosidase alfa.
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders
Julie Werenberg Dreier, PhD1,2; Marte-Helene Bjørk, PhD2,3; Silje Alvestad, PhD2,4; Mika Gissler, PhD5,6,7; Jannicke Igland, PhD8,9; Maarit K. Leinonen, PhD5; Yuelian Sun, PhD1,10,11,12; Helga Zoega, PhD13,14; Jacqueline M. Cohen, PhD15,16; Kari Furu, PhD15,16; Torbjörn Tomson, PhD17; Jakob Christensen, DrMedSci1,10,12
doi : 10.1001/jamaneurol.2023.0674
Importance Prenatal antiseizure medication (ASM) exposure has been associated with adverse early neurodevelopment, but associations with a wider range of psychiatric end points have not been studied.
Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe Epilepsy
Sattar Khoshkhoo, MD1,2,3; Yilan Wang, BS2,4; Yasmine Chahine, BS2; E. Zeynep Erson-Omay, PhD5; Stephanie M. Robert, MD, PhD5; Emre Kiziltug, BS5; Eyiyemisi C. Damisah, MD5; Carol Nelson-Williams, MS6; Guangya Zhu, PhD7; Wenna Kong, BS7; August Yue Huang, PhD2,3,8; Edward Stronge, BS2,9; H. Westley Phillips, MD2,3,10; Brian H. Chhouk, BS2; Sara Bizzotto, PhD11; Ming Hui Chen, MD, MMSc2; Thiuni N. Adikari, BMSc12; Zimeng Ye, MS12; Tom Witkowski, BSc12; Dulcie Lai, PharmD, PhD13; Nadine Lee2; Julie Lokan, MBBS14; Ingrid E. Scheffer, MBBS, PhD12,15,16,17,18; Samuel F. Berkovic, MD12,18; Shozeb Haider, PhD19; Michael S. Hildebrand, PhD12,15; Edward Yang, MD, PhD20; Murat Gunel, MD5; Richard P. Lifton, MD, PhD6,21; R. Mark Richardson, MD, PhD22; Ingmar Blümcke, MD23,24; Sanda Alexandrescu, MD25; Anita Huttner, MD26; Erin L. Heinzen, PharmD, PhD13,27; Jidong Zhu, PhD7; Annapurna Poduri, MD, MPH28; Nihal DeLanerolle, DPhil, DSc5; Dennis D. Spencer, MD5; Eunjung Alice Lee, PhD2,3,8; Christopher A. Walsh, MD, PhD2,3,29,30,31; Kristopher T. Kahle, MD, PhD2,3,21,32
doi : 10.1001/jamaneurol.2023.0473
Importance Mesial temporal lobe epilepsy (MTLE) is the most common focal epilepsy subtype and is often refractory to antiseizure medications. While most patients with MTLE do not have pathogenic germline genetic variants, the contribution of postzygotic (ie, somatic) variants in the brain is unknown.
Focal Cortex Stimulation With a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Single-Arm Trials
Andreas Schulze-Bonhage, MD1,2,3,4; Martin Hirsch, MD1; Susanne Knake, MD5; Elisabeth Kaufmann, MD6; Josua Kegele, MD7; Michael Rademacher, MD8; Kristl Vonck, MD, PhD9; Volker Arnd Coenen, MD10,11,12; Martin Glaser, MD13; Carolin Jenkner, PhD14,15; Yaroslav Winter, MD5,15; Sergiu Groppa, MD, PhD16; for the EASEE Study Group
doi : 10.1001/jamaneurol.2023.0066
Importance For the large population of people with drug-refractory epilepsy, alternative treatment approaches are needed. Clinical trial outcomes of a novel stimulation device, which is newly available in Europe for the treatment of patients with a predominant seizure focus, are reported for the first time.
Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes
Chris Moran, PhD1,2,3,4; Mary E. Lacy, PhD5,6; Rachel A. Whitmer, PhD5,7; Ai-Lin Tsai, MS5; Charles P. Quesenberry, PhD5; Andrew J. Karter, PhD5; Alyce S. Adams, PhD5,8; Paola Gilsanz, PhD5,9
doi : 10.1001/jamaneurol.2023.0697
Importance The levels of glycemic control associated with the lowest risk of dementia in people with type 2 diabetes are unknown. This knowledge is critical to inform patient-centered glycemic target setting.
Association of Mortality and Risk of Epilepsy With Type of Acute Symptomatic Seizure After Ischemic Stroke and an Updated Prognostic Model
Lucia Sinka1; Laura Abraira, MD, PhD2; Lukas L. Imbach, MD, MSc3; Dominik Zieglgänsberger, MD4; Estevo Santamarina, MD2; José Ã�lvarez-SabÃn, PhD2; Carolina Ferreira-Atuesta, MD, MSc5,6,7; Mira Katan, MD, MSc1,8; Natalie Scherrer, MD1; Giulio Bicciato, MD1; Robert Terziev, MD1; Cyril Simmen1; Kai Michael Schubert, PhD1; Adham Elshahabi, MD1; Christian R. Baumann, MD1; Nico Döhler, MD4,9; Barbara Erdélyi-Canavese, MD4; Ansgar Felbecker, MD4; Philip Siebel, MD4; Michael Winklehner, MD10,11; Tim J. von Oertzen, MD10; Judith N. Wagner, MD10; Gian Luigi Gigli, MD12; Anna Serafini, MD12; Annacarmen Nilo, MD12; Francesco Janes, PhD12; Giovanni Merlino, PhD12; Mariarosaria Valente, MD12; MarÃa Paula Zafra-Sierra, MD13; Hernan Bayona-Ortiz, MD13; Julian Conrad, MD14,15; Stefan Evers, MD, PhD14,16; Piergiorgio Lochner, MD17; Frauke Roell, MD17; Francesco Brigo, MD18; Carla Bentes, PhD19; Ana Rita Peralta, MD19; Teresa Pinho e Melo, MD19; Mark R. Keezer, MDCM20,21; John S. Duncan, DM5,7; Josemir W. Sander, MD, PhD5,7,20; Barbara Tettenborn, MD4; Matthias J. Koepp, MD, PhD5,7; Marian Galovic, MD, PhD1,5,7
doi : 10.1001/jamaneurol.2023.0611
Importance Acute symptomatic seizures occurring within 7 days after ischemic stroke may be associated with an increased mortality and risk of epilepsy. It is unknown whether the type of acute symptomatic seizure influences this risk.
Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease
Antoine Leuzy, PhD1; Alexa Pichet Binette, PhD1; Jacob W. Vogel, PhD2,3; Gregory Klein, PhD4; Edilio Borroni, PhD4; Matteo Tonietto, PhD4; Olof Strandberg, PhD1; Niklas Mattsson-Carlgren, MD, PhD1,5,6; Sebastian Palmqvist, MD, PhD1,7; Michael J. Pontecorvo, PhD8,9; Leonardo Iaccarino, PhD8,9; Erik Stomrud, MD, PhD1,7; Rik Ossenkoppele, PhD1,10,11; Ruben Smith, MD, PhD1,5; Oskar Hansson, MD, PhD1,7; for the Alzheimer’s Disease Neuroimaging Initiative
doi : 10.1001/jamaneurol.2023.1067
Importance Longitudinal tau positron emission tomography (PET) is a relevant outcome in clinical trials evaluating disease-modifying therapies in Alzheimer disease (AD). A key unanswered question is whether the use of participant-specific (individualized) regions of interest (ROIs) is superior to conventional approaches where the same ROI (group-level) is used for each participant.
Characteristics of Progressive Multifocal Leukoencephalopathy Associated With Sarcoidosis Without Therapeutic Immune Suppression
Caleb R. S. McEntire, MD1; Anita Fletcher, MD2; Michel Toledano, MD3; Samantha Epstein, MD4; Emily White, MD5; C. Sabrina Tan, MD6,7; Yang Mao-Draayer, MD, PhD8; Samantha A. Banks, MD3; Allen J. Aksamit, MD3; Jeffrey M. Gelfand, MD9; Kiran T. Thakur, MD10; Pria Anand, MD5; Irene Cortese, MD11; Shamik Bhattacharyya, MD12
doi : 10.1001/jamaneurol.2023.0841
Importance Progressive multifocal leukoencephalopathy can occur in the context of systemic sarcoidosis (S-PML) in the absence of therapeutic immune suppression and can initially be mistaken for neurosarcoidosis or other complications of sarcoidosis. Earlier recognition of S-PML could lead to more effective treatment of the disease.
Rheumatoid Arthritis and Risk of Parkinson Disease in Korea
Jihun Kang, MD, PhD1; Yeonghee Eun, MD, PhD2; Wooyoung Jang, MD, PhD3; Mi Hee Cho, MD4; Kyungdo Han, PhD5; Jinhyoung Jung, PhD6; Yunkyung Kim, MD, PhD7; Gun-tae Kim, MD, PhD7; Dong Wook Shin, MD, PhD, DrPH8,9; Hyungjin Kim, MD, PhD10,11
doi : 10.1001/jamaneurol.2023.0932
Importance Although it has been postulated that chronic inflammation caused by rheumatoid arthritis (RA) contributes to the development of Parkinson disease (PD), the association between these 2 conditions has yet to be determined.
Severe Hippocampal Atrophy in a Patient With Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy
Frederik Bartels, MD1,2,3; Josephine Heine, PhD1; Carsten Finke, MD1,3
Lentiform Fork Sign on Magnetic Resonance Imaging After Methamphetamine and Alcohol Misuse
Juliane Hiesgen, Dr med1; Jacques Badenhorst, MBChB2
Trends in the Prevalence of Stroke Among Community-Dwelling Individuals in the US, 1999-2018
Wells Andres, MD1; Aaron Rothstein, MD1; Holly Elser, MD, PhD1; Kelly L. Sloane, MD1; Rebecca F. Gottesman, MD, PhD2; Scott E. Kasner, MD, MSCE1,3; Andrea L. C. Schneider, MD, PhD1,3
